EMA database aids safety monitoring
A study conducted by the European Medicines Agency (EMA) has shown that statistical methods using the EMA?s EudraVigilance database of adverse drug reaction reports can be used to detect drug safety issues "significantly earlier" compared with routine pharmacovigilance.
A study conducted by the European Medicines Agency (EMA) has shown that statistical methods using the EMA’s EudraVigilance database of adverse drug reaction reports can be used to detect drug safety issues “significantly earlier” compared with routine pharmacovigilance.
The study was published in Drug Safety, the journal of the International Society of Pharmacovigilance, and was conducted in relation to centrally authorised medicines. The EMA used a statistical signal detection method in the EudraVigilance database and found that safety issues could be detected earlier in about 54% of cases where a clinically important adverse drug reaction report was found (compared with routine pharmacovigilance).
According to a press statement from the EMA, the study “provides direct evidence for a strong additive role of Eudravigilance signal detection methods”. The agency also claims that the study underlines the importance of well established pharmacovigilance systems, such as active surveillance or the periodic safety update reporting, and concludes “a combination of routine pharmacovigilance and statistical signal detection provides the optimal safety monitoring with earlier detection and better management of safety issues”.
Although the study looks at statistical signal detection retrospectively, the EMA says it now routinely uses the method to strengthen signal detection for centrally authorised medicines to help it detect new or changing safety issues with medicines earlier.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
